Related Experiment Video
Updated: Feb 9, 2026
15:43
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
23.9K
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
Nicole Mayer-Hamblett1,2,3, George Retsch-Bogart4, Margaret Kloster3
11 Department of Pediatrics and.
Summary
Adding azithromycin to tobramycin inhalation solution (TIS) significantly reduced pulmonary exacerbations in children with cystic fibrosis and early Pseudomonas aeruginosa (Pa) infection. This combination therapy also improved weight gain but did not affect bacterial recurrence.
Area of Science:
- Pediatric Pulmonology
- Infectious Diseases
- Clinical Trials
Background:
- Pseudomonas aeruginosa (Pa) infection is a significant concern in cystic fibrosis (CF) management.
- Early Pa infection in CF is typically treated with inhaled antipseudomonal antibiotics like tobramycin inhalation solution (TIS).
- Complementary therapies reducing pulmonary exacerbations and inflammation may prolong time to Pa recurrence.
Purpose of the Study:
- To evaluate if adding azithromycin to TIS reduces pulmonary exacerbations and delays Pa recurrence in children with CF and early Pa.
- To assess the impact of this combination therapy on clinical and safety outcomes.
Main Methods:
- The OPTIMIZE trial was an 18-month, multicenter, double-blind, randomized, placebo-controlled study.
- Participants (6 months to 18 years) with early Pa received azithromycin or placebo three times weekly alongside standardized TIS.
- Primary endpoint: time to pulmonary exacerbation; secondary endpoint: time to Pa recurrence.
Main Results:
- Enrollment was stopped early due to demonstrated efficacy.
- Azithromycin significantly reduced the risk of pulmonary exacerbation by 44% (HR, 0.56; P=0.004).
- A significant increase in weight was observed in the azithromycin group (1.27 kg, P=0.046), with no impact on microbiological outcomes.
Conclusions:
- Azithromycin combined with TIS significantly reduces pulmonary exacerbations in children with CF and early Pa.
- This regimen also leads to sustained weight improvement.
- Azithromycin did not influence microbiological outcomes or time to Pa recurrence in this population.
More Related Videos
11:20Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos
Published on: May 12, 2020
7.0K
07:46Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
34.1K
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
891
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
891
01:24Cystic Fibrosis: Management
546
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
546
01:11Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
01:12Trial and Error and Algorithm
425
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
425
01:16Clinical Trials
10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.8K
01:04Random Error
9.8K
Random or indeterminate errors originate from various uncontrollable variables, such as variations in environmental conditions, instrument imperfections, or the inherent variability of the phenomena being measured. Usually, these errors cannot be predicted, estimated, or characterized because their direction and magnitude often vary in magnitude and direction even during consecutive measurements. As a result, they are difficult to eliminate. However, the aggregate effect of these errors can be...
9.8K